Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Gilead's Remdesivir Results Encouraging, Safety Brings Skepticism

Executive Summary

Analysts see NIAID’s placebo-controlled data as more important than Gilead’s open-label data. Quick emergency use authorization by FDA is possible, but the US agency has not confirmed EUA.

You may also be interested in...



Gilead Ramps Up Remdesivir Manufacturing, Advances Inhaled Formulation

Gilead will study inhalable remdesivir in volunteers, then hopefully in August as an earlier COVID-19 treatment. Analyst says production of 2m-plus I.V. doses by year-end could mean blockbuster revenues.

Questions Remain On Gilead’s Remdesivir

Remdesivir shows ability to yield clinical improvement in moderately ill COVID-19 patients, but data are called ‘modest’ and shorter therapy duration showed better results than longer.

More Remdesivir Data, More Questions Linger

The latest data on the NIAID’s ACTT-1 study offers more help for clinicians trying to determine which coronavirus patients should receive remdesivir, but selection criteria – and supply – remain uncertain.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

MT142464

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel